HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

2015 In Review: Legislative Letdowns Weigh On Industry And NGOs Alike

This article was originally published in The Rose Sheet

Executive Summary

The US Sunscreen Innovation Act's implementation, which has frustrated TEA sponsors, Congress and public-health advocates, was a hot topic for "Rose Sheet" readers in 2015, as well as a lawsuit in the EU that could greatly dilute the European ban on cosmetic animal testing, much to animal-welfare groups' dismay.

You may also be interested in...



EWG To FDA Commish: Sunscreen SPFs Require ‘Urgent’ Investigation

The Environmental Working Group renews its call for a cap on SPF values at 50+, asking FDA to investigate whether anti-inflammatory ingredients added to sunscreen formulations are boosting SPFs without providing meaningful protection against UV damage. The NGO also recommends changes to the agency’s SPF testing requirements to improve the accuracy of labeled SPF claims.

Highest European Court To Rule On Animal-Testing Ban's Scope In 2016

The EU's ban on animal-tested cosmetics and ingredients could be narrowly limited to tests performed to meet the European Cosmetics Regulation's data requirements – exempting testing undertaken to comply with third-country regulations or other EU laws – if the European Court of Justice sides with industry next year. Stakeholders expect the court's advocate general to render an opinion on the matter in March 2016.

FDA Drafts Guidance On Safety-Data Musts For GRASE Sunscreen Actives

Time and extent applicants seeking GRASE status for UV filters should provide FDA with the kind of clinical safety data used to support approval of chronic-use cutaneous drug products, and nonclinical testing should focus on potential long-term adverse effects, according to newly released draft guidance required from the agency under the Sunscreen Innovation Act. FDA is particularly interested in receiving comments about final formulation safety testing it anticipates requiring under specified monograph conditions.

Related Content

Topics

UsernamePublicRestriction

Register

RS019812

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel